Ocugen’s Gene Therapy Cuts Geographic Atrophy Growth by 46%
Ocugen’s modifier gene therapy achieved a 46% reduction in geographic atrophy lesion growth, indicating potential efficacy in treating advanced dry AMD. This result positions the company within the expanding gene therapy segment of the $9.86 billion longevity biotech market, projected to reach $29.7 billion by 2034.
1. Efficacy Signal for Geographic Atrophy
Ocugen’s modifier gene therapy showed a 46% reduction in geographic atrophy lesion growth in an interim analysis, indicating robust potential to slow vision loss in advanced dry AMD. The result highlights the therapy’s mechanism of targeting molecular drivers of retinal degeneration.
2. Market Opportunity and Competitive Edge
Geographic atrophy affects over 5 million patients worldwide and currently lacks approved gene-based treatments, creating a potential multibillion-dollar market. Ocugen’s positive efficacy signal positions it as a frontrunner among emerging gene therapy developers in the longevity biotech sector.